Skip to main navigation menu Skip to main content Skip to site footer

No. 1 (2023)

PSYCHOPHARMACOTHERAPY

Potential Role of Third Generation Antipsychotics in Reducing Dependence in Patients with Bipolar Disorder

https://doi.org/10.21265/PSYPH.2023.46.35.002

Published 2023-03-30

  • A.R. Asadullin
    • ,
  • K.A. Gasenko

A.R. Asadullin
Bashkir State Medical Universityof the Ministry of Health of Russia, M. Bekhterev National Medical Research Center for Neurology and Psychiatry, State Budgetary Institution of Healthcare of the Republic of Bashkortostan Republican Clinical Psychotherapy Center of the Ministry of Health of the Republic of Bashkortostan

K.A. Gasenko
Budgetary Healthcare Institution of Omsk region “Clinical Psychiatric Hospital named after N.N. Solodnikov”

Abstract

The mesolimbic dopamine system plays a key role in the pathogenesis of psychiatric disorders (schizophrenia, bipolar disorder (BD), etc.) and the development of substance use disorders (SUDs).Common genetic markers and underlying cellular processes, such as kindling, physiological and behavioral changes induced by repeated repetition of low-intensity stimuli, confirm the close relationship between these disorders, which also turns into a high level of comorbidity. Dopamine partial agonists represent a new class of antipsychotics with novel pharmacodynamic properties. Two of them including Cariprazine have been approved by the US Food and Drug Administration (FDA) for the treatment of bipolar disorder. At the same time, the expediency of using partial dopamine agonists/antagonists acting on D2- and D3-receptors, in treatment of SUDs is not so unambiguous. However, recent studies have shown that dopamine D3-receptors play a critical role in the development of SUDs and BD. Therefore, it can be assumed that D2/D3 receptor partial agonists/antagonists can be considered a potentially effective class of drugs for the treatment of both disorders. This descriptive review discusses the prospects for the use of these drugs in the treatment of psychiatric disorders, especially in patients with comorbid disorders (BD and SUD).

Keywords

substance use disorder, cariprazine, psychopharmacotherapy, partial agonist, antipsychotic, bipolar disorder

PDF (Русский)

References

  1. Мосолов С.Н., Костюкова Е.Г. Биполярное расстройство // Психиатрия: национальное руководство / под ред. Н.Г. Незнанова, Ю.А. Александровского. – М.: Эхо, 2018. – С. 379–439.
  2. Mullins N., Forstner A.J., O’Connell K.S. et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology // Nature Genetics. – 2021. – Vol. 53, no. 6. – Pp. 817–829. – DOI: https://doi.org/10.1038/s41588-021-00857-4
  3. Miller J.N., Black D.W. Bipolar disorder and suicide: a review // Current Psychiatry Reports. – 2020. – Vol. 22, no. 2. – Pp. 1–10. – DOI: https://doi.org/10.1007/s11920-020-1130-0
  4. Мосолов С.Н., Костюкова Е.Г., Кузавкова М.В. Биполярное аффективное расстройство: диагностика и терапия. – М.: МЕДпресс-информ, 2008. – 384 с.
  5. Gordovez F.J.A., McMahon F.J. The genetics of bipolar disorder // Molecular Psychiatry. – 2020. – Vol. 25, no. 3. – Pp. 544–559. – DOI: https://doi.org/10.1038/s41380-019-0634-7
  6. Grunze H., Schaefer M., Scherk H. et al. Comorbid bipolar and alcohol use disorder — a therapeutic challenge // Frontiers in Psychiatry. – 2021. – Vol. 12. – Pp. 24–32. – DOI: https://doi.org/10.3389/fpsyt.2021.660432
  7. Lalli M., Brouillette K., Kapczinski F. et al. Substance use as a risk factor for bipolar disorder: a systematic review // Journal of Psychiatric Research. – 2021. – Vol. 144. – Pp. 285– 295. – DOI: https://doi.org/10.1016/j.jpsychires.2021.10.012
  8. Menculini G., Steardo Jr L., Verdolini N. et al. Substance use disorders in bipolar disorders: Clinical correlates and treatment response to mood stabilizers // Journal of Affective Disorders. – 2022. – Vol. 300. – Pp. 326–333. – DOI: https://doi.org/10.1016/j.jad.2022.01.001
  9. Wang, Z., Li T., Li S. et al. The prevalence and clinical correlates of medical disorders comorbidities in patients with bipolar disorder // BMC Psychiatry. – 2022. – Vol. 22, no. 1. – Pp. 1–9. – DOI: https://doi.org/10.1186/s12888-022-03819-0
  10. Altinbas K., Evren C. Comorbid substance use disorder in bipolar disorder: A hard rock to roll on the treatment road // Dusunen Adam. – 2021. – Vol. 34, no. 2. – Pp. 111–113. – DOI: https://doi.org/10.14744/DAJPNS.2021.00128
  11. Burdick K.E., Millett C.E., Yocum A. K et al. Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative // Bipolar Disorders. – 2022. – Vol. 24 (7). – Pp. 709–719. – DOI: https://doi.org/10.1111/bdi.13208
  12. Schneider F., Erhart M., Hewer W. et al. Mortality and medical comorbidity in the severely mentally ill: a German registry study // Deutsches Ärzteblatt International. – 2019. – Vol. 116, no. 23–24. – P. 405. – DOI: https://doi.org/10.3238/arztebl.2019.0405
  13. Preuss U.W., Schaefer M., Born C. et al. Bipolar disorder and comorbid use of illicit substances // Medicina. – 2021. – Vol. 57, no. 11. – Pp. 12–56. – DOI: https://doi.org/10.3390/medicina57111256
  14. Post R.M., Altshuler L.L., Kupka R. et al. 25 Years of the International Bipolar Collaborative Network (BCN) // International Journal of Bipolar Disorders. – 2021. – Vol. 9, no. 1. – Pp. 1–10. – DOI: https://doi.org/10.1186/s40345-020-00218-w
  15. Grover S., Avasthi A., Chakravarty R. et al. Prevalence and association of comorbid substance dependence on the course and outcome of bipolar disorder: Findings from the bipolar disorder course and outcome study from India (BiD-CoIN study) // Indian Journal of Psychiatry. – 2022. – Vol. 64, no. 5. – Pp. 449–456. – DOI: https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_665_21
  16. Грунце А., Борн К., Грунце Х. Влияние курения на течение и прогноз биполярного расстройства // Современная терапия психических расстройств. – 2022. – № 1. – С. 2–9. – DOI: https://doi.org/10.21265/PSYPH.2022.60.1.001
  17. Grunze A., Mosolov S., Grunze H., Born C. The detrimental effects of smoking on the course and outcome in adults with bipolar disorder — A narrative review // Front Psychiatry. – 2023. – Vol. 13. – Art. 1114432. – DOI: https://doi.org/10.3389/fpsyt.2022.1114432
  18. Suh J.J., Ruffins S., Robins C.E. et al. Self-medication hypothesis: Connecting affective experience and drug choice // Psychoanalytic Psychology. – 2008. – Vol. 25, no. 3. – Art. 518. – DOI: https://doi.org/10.1037/0736-9735.25.3.518
  19. Khokhar J.Y., Dwiel L.L., Henricks A.M. et al. The link between schizophrenia and substance use disorder: A unifying hypothesis // Schizophrenia Research. – 2018. – Vol. 194. – Pp. 78–85. – DOI: https://doi.org/10.1016/j.schres.2017.04.016
  20. Lembke A. Time to abandon the self-medication hypothesis in patients with psychiatric disorders // The American Journal of Drug and Alcohol Abuse. – 2012. – Vol. 38, no. 6. – Pp. 524–529. – DOI: https://doi.org/10.3109/00952990.2012.694532
  21. Gómez-Coronado N., Sethi R., Bortolasci C.C. et al. A review of the neurobiological underpinning of comorbid substance use and mood disorders // Journal of Affective Disorders. – 2018. – Vol. 241. – Pp. 388–401. – DOI: https://doi.org/10.1016/j.jad.2018.08.041
  22. Асадуллин А.Р., Ахметова Э.А., Урицкий Б.Л. «Синтетическая» наркомания: гены дофаминергической системы в вопросе употребления синтетических каннабиноидов подростками // Психическое здоровье. – 2018. – Т. 16, №. 3. – С. 11–12.
  23. Асадуллин А.Р., Юлдашев В.Л., Николаев И.В. и др. Полиморфные варианты гена рецептора дофамина drd4 у лиц, употребляющих и не употребляющих синтетические катиноны // Неврологический вестник. – 2017. – № 49 (1). – С. 30–33
  24. Flace P., Livrea P., Basile G.A. et al. The cerebellar dopaminergic system // Frontiers in Systems Neuroscience. – 2021. – Vol. 15. – Pp. 614–650. – DOI: https://doi.org/10.3389/fnsys.2021.650614
  25. Li M., Zhou L., Sun X. et al. Dopamine, a co-regulatory component, bridges the central nervous system and the immune system // Biomedicine & Pharmacotherapy. – 2022. – Vol. 145. – Pp. 12–45. – DOI: https://doi.org/10.1016/j.biopha.2021.112458
  26. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system // Pharmacological Reviews. – 1959. – Vol. 11, no. 2. – Pp. 490–493.
  27. Ballester P.L., Romano M.T., de Azevedo Cardoso T. et al. Brain age in mood and psychotic disorders: a systematic review and meta-analysis // Acta Psychiatrica Scandinavica. – 2022. – Vol. 145, no. 1. – Pp. 42–55. – DOI: https://doi.org/10.1111/acps.13371
  28. Goddard G.V., McIntyre D.C., Leech C.K. A permanent change in brain function resulting from daily electrical stimulation // Experimental Neurology. – 1969. – Vol. 25, no. 3. – Pp. 295–330.
  29. von Rüden E.L., Wolf F., Keck M. et al. Genetic modulation of HSPA1A accelerates kindling progression and exerts pro-convulsant effects // Neuroscience. – 2018. – Vol. 386. – Pp. 108–120. – DOI: https://doi.org/10.1016/j.neuroscience.2018.06.031
  30. de Marco A., Scozia G., Manfredi L. et al. A Systematic review of genetic polymorphisms associated with bipolar disorder comorbid to substance abuse // Genes. – 2022. – Vol. 13, no. 8. – Pp. 03–13. – DOI: https://doi.org/10.3390/genes13081303
  31. Hunt G.E., Large M.M., Cleary M. et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis // Drug and alcohol Dependence. – 2018. – Vol. 191. – Pp. 234–258. – DOI: https://doi.org/10.1016/j.drugalcdep.2018.07.011
  32. Liu J., Li J. Drug addiction: a curable mental disorder? //Acta Pharmacologica Sinica. – 2018. – Vol. 39, no. 12. – Pp. 1823–1829. – DOI: https://doi.org/10.1038/s41401-018-0180-x
  33. Крупицкий Е.М., Ахметова Э.А., Асадуллин А.Р. Фармакогенетика химических зависимостей // Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. – 2019. – № 4–1. – С. 12–20.
  34. Shadrina M., Bondarenko E.A., Slominsky P.A. Genetics factors in major depression disease // Frontiers in Psychiatry. – 2018. – Vol. 9. – Art. 334. – DOI: https://doi.org/10.3389/fpsyt.2018.00334
  35. Zhao L., Lin Y., Lao G. et al. Association study of dopamine receptor genes polymorphism with cognitive functions in bipolar I disorder patients // Journal of Affective Disorders. – 2015. – Vol. 170. – Pp. 85–90. – DOI: https://doi.org/10.1016/j.jad.2014.08.039
  36. Мосолов С.Н., Алфимов П.В. Роль дофаминовых D3-рецепторов в механизме действия современных антипсихотиков // Современная терапия психических расстройств. – 2014. – № 1. – С. 2–9.
  37. Heidbreder C.A., Newman A.H. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders // Annals of the New York Academy of Sciences. – 2010. – Vol. 1187, no. 1. – Pp. 4–34. – DOI: https://doi.org/10.1111/j.1749-6632.2009.05149.x
  38. Tretyak V., Kirsch D.E., Le V. et al. Coping drinking motives, neural functional coupling during emotion processing, and alcohol use in young adults with bipolar disorder // Alcoholism: Clinical and Experimental Research. – 2022. – Vol. 46, no. 8. – Pp. 1482–1496. – DOI: https://doi.org/10.1111/acer.14885
  39. You Z.B., Bi G.H., Galaj E. et al. Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects // Neuropsychopharmacology. – 2019. – Vol. 44, no. 8. – Pp. 1415–1424. – DOI: https://doi.org/10.1038/s41386-018-0284-5
  40. Worhunsky P.D., Angarita G.A., Zhai Z.W. et al. Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder // Neuropsychopharmacology. – 2021. – Vol. 46, no. 2. – Pp. 316–324. – DOI: https://doi.org/10.1038/s41386-020-00874-7
  41. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence // The Cocaine Crisis. – 1987, January. – Pp. 65–74. – DOI: https://doi.org/10.1007/978-1-4613-1837-8_7
  42. Pich E.M., Collo G. Pharmacological targeting of dopamine D3 receptors: possible clinical applications of selective drugs // European Neuropsychopharmacology. – 2015. – Vol. 25, no. 9. – Pp. 1437–1447. – DOI: https://doi.org/10.1016/j.euroneuro.2015.07.012
  43. Calabrese F., Tarazi F.I., Racagni G. et al. The role of dopamine D3 receptors in the mechanism of action of cariprazine // CNS Spectrums. – 2020. – Vol. 25, no. 3. – Pp. 343–351. – DOI: https://doi.org/10.1017/S109285291900083X
  44. Truong T.T., Li B. Case series: cariprazine for treatment of methamphetamine use disorder // The American Journal on Addictions. – 2022. – Vol. 31, no. 1. – Pp. 85–88. – DOI: https://doi.org/10.1111/ajad.13241
  45. Murthy P., Mahadevan J., Chand P.K. Treatment of substance use disorders with co-occurring severe mental health disorders // Current Opinion in Psychiatry. – 2019. – Vol. 32, no. 4. – Pp. 293–299. – DOI: https://doi.org/10.1097/YCO.0000000000000510
  46. Костюкова Е.Г., Мосолов С.Н. Алгоритм биологической терапии депрессии при биполярном аффективном расстройстве // Современная терапия психических расстройств. – 2020. – № 4. – С. 36–45.
  47. Earley W., Burgess M.V., Rekeda L. et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study // American Journal of Psychiatry. – 2019. – Vol. 176, no. 6. – Pp. 439–448. – DOI: https://doi.org/10.1176/appi.ajp.2018.18070824
  48. Медведев В.Э. Карипразин — современный препарат для лечения шизофрении и биполярного расстройства // Современная терапия психических расстройств. – 2022. – № 3. – С. 51–57. – DOI: https://doi.org/10.21265/PSYPH.2022.46.63.006
  49. Volkow N.D. Personalizing the treatment of substance use disorders // American Journal of Psychiatry. – 2020. – Vol. 177, no. 2. – Pp. 113–116. – DOI: https://doi.org/10.1176/appi.ajp.2019.19121284
  50. Volkow N.D., Woodcock J., Compton W.M. et al. Medication development in opioid addiction: meaningful clinical end points // Science Translational Medicine. – 2018. – Vol. 10, no. 434. – Pp. 25–95. – DOI: https://doi.org/10.1126/scitranslmed.aan25
  51. Stahl S.M., Laredo S., Morrissette D.A. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data // Therapeutic Advances in Psychopharmacology. – 2020. – Vol. 10. – Art. 2045125320905752. – DOI: https://doi.org/10.1177/2045125320905
  52. Caricasole V., Spagnolo G., Di Bernardo I. et al. Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder // Comprehensive Psychiatry. – 2019. – Vol. 94. – Art. 152126. – DOI: https://doi.org/10.1016/j.comppsych.2019.152126
  53. Ricci V., Di Salvo G., Maina G. Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report // Journal of Addictive Diseases. – 2022. – Vol. 40, no. 1. – Pp. 145–148. – DOI: https://doi.org/10.1080/10550887.2021.1945398
  54. Gao K., Chen D., Robison A.J. et al. Proteome-informed machine learning studies of cocaine addiction // The Journal of Physical Chemistry Letters. – 2021. – Vol. 12, no. 45. – Pp. 11122–11134. – DOI: https://doi.org/10.1021/acs.jpclett.1c03133
  55. Rodriguez Cruz J., SahlstenSchölin J., Hjorth S. Case report: cariprazine in a patient with schizophrenia, substance abuse, and cognitive dysfunction // Frontiers in Psychiatry. – 2021. – Art. 1419. – DOI: https://doi.org/10.3389/fpsyt.2021.727666
  56. Wesołowska A., Partyka A., Jastrzębska-Więsek M. et al. The preclinical discovery and development of cariprazine for the treatment of schizophrenia // Expert Opinion on Drug Discovery. – 2018. – Vol. 13, no. 8. – Pp. 779–790. – DOI: https://doi.org/10.1080/17460441.2018.1471057

Downloads

Download data is not yet available.